Method of inducing a cross-reactive HIV-1 immune response by administering a composition comprising the GBV-C E2 protein
AssigneesUniversity of Iowa Research Foundation, The United States of America as represented by the Secretary of the Department of Veterans Affairs
InventorsJack T. Stapleton, Jinhua Xiang, Donna Klinzman, James H. McLinden
Life of this patent
Estimating the term…
Abstract
GB virus C (GBV-C or hepatitis G virus) is a flavivirus that frequently leads to chronic viremia in humans. The invention provides compositions and methods involving an anti-GBV-C antibody or other GBV-C binding agent, or a GBV-C antigen, for inhibiting and treating HIV infections.
Claims5
A method of inducing a cross-reactive anti-HIV-1 immune response in a subject comprising contacting said subject with an immunogenic composition comprising a GBV-C E2 polypeptide or fragment thereof comprising an epitope defined by GGAGLTGGFYEPLVRRC (SEQ ID NO:7) dispersed in a pharmaceutical carrier, buffer or medium.
Dependencies are inferred from the claim text.